Expression of Concern: Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors.

Expression of Concern: Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors.

Bibliographic Details
Main Author:	PLOS ONE Editors
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2019-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC6459487?pdf=render

Similar Items

Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors.
by: Floriana Morgillo, et al.
Published: (2011-01-01)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
by: Xu H, et al.
Published: (2019-07-01)

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
by: Svenja Wagener-Ryczek, et al.
Published: (2020-05-01)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
by: Lihua Huang, et al.
Published: (2015-09-01)

Expression of Concern: Autophagosome-Mediated EGFR Down-Regulation Induced by the CK2 Inhibitor Enhances the Efficacy of EGFR-TKI on EGFR-Mutant Lung Cancer Cells with Resistance by T790M.
by: PLOS ONE Editors
Published: (2019-01-01)

Mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
by: Gergis, Carol
Published: (2019)

Radiofrequency Ablation with Continued EGFR Tyrosine Kinase Inhibitor Therapy Prolongs Disease Control in EGFR-Mutant Advanced Lung Cancers with Acquired Resistance to EGFR Tyrosine Kinase Inhibitors: Two Case Reports
by: Shi X, et al.
Published: (2020-07-01)

Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells.
by: Keisuke Tabara, et al.
Published: (2012-01-01)

Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity
by: Lynnette Marcar, et al.
Published: (2019-06-01)

Mechanisms of acquired resistance to tyrosine kinase inhibitors
by: Yi-fan Chen, et al.
Published: (2011-12-01)

Design and Discovery of Quinazoline- and Thiourea-Containing Sorafenib Analogs as EGFR and VEGFR-2 Dual TK Inhibitors
by: Shaofeng Sun, et al.
Published: (2017-12-01)

The Role of Cigarette Smoke-Derived Carcinogens in Influencing the Antitumor Activity of EGFR Tyrosine Kinase Inhibitors
by: Shu-Lin Wang, et al.
Published: (2013)

Effects of Sorafenib, a Tyrosin Kinase Inhibitor, on Adrenocortical Cancer
by: Lidia Cerquetti, et al.
Published: (2021-05-01)

Advances in studies of tyrosine kinase inhibitors and their acquired resistance
by: Qinlian Jiao, et al.
Published: (2018-02-01)

Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
by: Toshio Fujino, MD, et al.
Published: (2021-03-01)

A case of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with MET amplification and epithelial-to-mesenchymal transition
by: Miyoshi S, et al.
Published: (2015-04-01)

Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2
by: Frangky Sangande, et al.
Published: (2020-10-01)

Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
by: Eric Santoni-Rugiu, et al.
Published: (2019-07-01)

Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression.
by: Kathryn E Ware, et al.
Published: (2010-11-01)

Effect of Sialylation on EGFR Function and Resistance to Tyrosine Kinase Inhibitor Gefitinib
by: Hsin-Yung Yen, et al.
Published: (2014)

Mechanisms of Acquired Resisitance to EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer
by: Hongjie LI, et al.
Published: (2009-12-01)

Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling
by: Yu D, et al.
Published: (2021-02-01)

High expression of hypoxia inducible factor 1α related with acquired resistant to EGFR tyrosine kinase inhibitors in NSCLC
by: Qian Jin, et al.
Published: (2021-01-01)

Synthesis, Anticancer Screening of Some Novel Trimethoxy Quinazolines and VEGFR2, EGFR Tyrosine Kinase Inhibitors Assay; Molecular Docking Studies
by: Abdulmalik S. Altamimi, et al.
Published: (2021-05-01)

A case report of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with T790M mutation and epithelial-to-mesenchymal transition
by: Nana Zhang, et al.
Published: (2017-01-01)

Resveratrol Decreases the Resistance of Lung Cancer Cells to EGFR Tyrosine Kinase Inhibitor
by: Chu-Ying Peng, et al.
Published: (2010)

Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor
by: Wang WX, et al.
Published: (2016-01-01)

EGFR-Specific Tyrosine Kinase Inhibitor Modifies NK Cell-Mediated Antitumoral Activity against Ovarian Cancer Cells
by: Nina Mallmann-Gottschalk, et al.
Published: (2019-09-01)

Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model
by: Collantes Maria, et al.
Published: (2010-05-01)

VEGFR1-tyrosine kinase signaling in pulmonary fibrosis
by: Hideki Amano, et al.
Published: (2021-06-01)

Expression of Concern: The in vitro and in vivo antitumor effects of clotrimazole on oral squamous cell carcinoma.
by: PLOS ONE Editors
Published: (2020-01-01)

Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.
by: Jeet Gandhi, et al.
Published: (2009-01-01)

EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors
by: Chenguang Li, et al.
Published: (2018-08-01)

Targeting <i>BRAF</i> Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer
by: Frank Aboubakar Nana, et al.
Published: (2021-09-01)

Expression of concern: Compensatory increase of transglutaminase 2 is responsible for resistance to mTOR inhibitor treatment.
by: PLOS ONE Editors
Published: (2020-01-01)

Acquired and Primary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
by: Shang-Gin Wu, et al.
Published: (2016)

Utilizing Reversible Bruton’s Tyrosine Kinase Inhibitors to Circumvent Acquired Resistance to Ibrutinib
by: Reiff, Sean
Published: (2018)

Squamous cell transformation as a mechanism of acquired resistance to tyrosine kinase inhibitor in EGFR‐mutated lung adenocarcinoma: a report of two cases
by: Hironori Uruga, et al.
Published: (2020-03-01)

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
by: Wang J, et al.
Published: (2016-06-01)

Role of IGF-binding protein 3 in the resistance of EGFR mutant lung cancer cells to EGFR-tyrosine kinase inhibitors.
by: Yun Jung Choi, et al.
Published: (2013-01-01)

Cannot write session to /tmp/vufind_sessions/sess_utgvee7bmtkfu3mi6781lmrgrn